LOPRESSOR
What it isBeta-1-selective antagonist for hypertension and angina; the succinate form also treats systolic heart failure.
Why this oneOnly extended-release metoprolol succinate carries heart-failure survival evidence; tartrate is not interchangeable.
What limits itBradycardia and hypotension limit it. CYP2D6 inhibitors or poor metabolism raise exposure; taper to avoid rebound ischemia.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Hypertension | Adult | 100 mg/day (QD or divided) | 100–450 mg/day | 450 mg/day |
| Angina pectoris | Adult | 100 mg/day divided BID | 100–400 mg/day | 400 mg/day |
| Myocardial infarction | Adult | 50 mg q6h ×48h (after IV metoprolol) | 100 mg BID maintenance |
Titration Titrate at weekly (or longer) intervals
Renal No adjustment needed
Hepatic Initiate at lower doses and titrate gradually (levels increase with poor hepatic function)
Pregnancy No demonstrated association with adverse developmental outcomes; crosses placenta — monitor neonate for hypotension, hypoglycemia, bradycardia, respiratory depression
Lactation Present in human milk (~0.5–2% of maternal weight-adjusted dose); no adverse infant reactions identified; monitor infant for beta-blockade
NO BOXED WARNINGS
Principal riskBradycardia; abrupt withdrawal can precipitate ischemia
Cost, est. cash$4–$80/month
Generic entry1993
Legacy pregnancy categoryC
Defining liabilityBradycardia and hypotension; overdose may cause cardiogenic shock and conduction block.

Open Metoprolol in the interactive console ↗

